Shares of Integer Holdings Co. (NASDAQ:ITGR) were down 3% on Wednesday . The stock traded as low as $22.65 and last traded at $22.82, with a volume of 78,899 shares changing hands. The stock had previously closed at $23.52.

Several analysts have weighed in on ITGR shares. TheStreet cut Integer Holdings from a “hold” rating to a “sell” rating in a research report on Friday, July 1st. Zacks Investment Research raised Integer Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, May 19th. Finally, Sterne Agee CRT reaffirmed a “buy” rating on shares of Integer Holdings in a research report on Monday, May 16th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Integer Holdings presently has an average rating of “Hold” and a consensus price target of $57.00.

The stock’s 50-day moving average is $0.00 and its 200-day moving average is $0.00. The firm’s market capitalization is $679.16 million.

Integer Holdings (NASDAQ:ITGR) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.70 by $0.14. The business had revenue of $348.38 million for the quarter, compared to analyst estimates of $356.72 million. The company’s revenue was up 99.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.73 earnings per share. Equities research analysts predict that Integer Holdings Co. will post $2.64 EPS for the current fiscal year.

Greatbatch, Inc is a developer and manufacturer of medical devices and components. The Company operates through two segments: Greatbatch Medical and QiG Group (QiG). Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.